This era can rightly be called, the era of "Transcriptome". After the succesful stories of RNA-seq and Microarrays, single cell RNA is a hot line.
As I always belived, if one has funds, one can go for a reasonable research. Same is true here. Since the scRNA-seq cost is really high, and several PIs cannot afford.
The question is: If someone performs scRNA-seq, but the results are contrasting to what was expected. What are the possible ways to value the wasted cost?